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INTRODUCTION: A LAWYER’S GUIDE TO 
CRISPR* 
JOHN M. CONLEY** 
This Symposium on Legal, Ethical, and Policy Implications of 
New Gene-Editing Technologies was motivated by recent scientific 
developments in the field of gene editing. For years, genomic 
medicine has been hailed as the future of clinical treatment. The 
general premise is that doctors will use detailed information about a 
particular patient’s DNA (and other “biomarkers”) to custom-tailor 
diagnoses, advice, drug choices and doses, and other specifics of 
treatment.1 President Obama’s highly publicized Precision Medicine 
Initiative2 (now rebranded—cryptically—as the “All of Us” Research 
Program)3 illustrates both the hope and the hype. 
Despite this hope and hype, genomic medicine has thus far had a 
limited effect on the day-to-day practice of medicine, and that effect 
has been most notable in cancer treatment (for example, the use of 
BRCA gene testing in treating breast cancer made famous by 
Angelina Jolie).4 The limiting factors have included the facts that (1) 
genes tend to influence the probability of getting a disease but rarely 
“cause” a disease in a deterministic sense; (2) the relative influences 
of environment, lifestyle, and epigenetic factors (changes in DNA’s 
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 1. See generally Alan Wong et al., Multiplexed Barcoded CRISPR-Cas9 Screening 
Enabled by CombiGEM, 113 PROC. NAT’L ACAD. SCI. 2544 (2016) (providing an 
overview of the ability to tailor diagnoses, drug choice, and treatment options through 
CRISPR-Cas9 screening of patients). 
 2. Press Release, Office of the Press Sec’y, White House, Fact Sheet: President 
Obama’s Precision Medicine Initiative (Jan. 30, 2015), https://obamawhitehouse.archives.gov/
the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative 
[https://perma.cc/9U9H-8H7N]. 
 3. See All of Us Research Program, ALL OF US, https://www.joinallofus.org/en 
[https://perma.cc/3HCR-2EJJ]. 
 4. See, e.g., Angelina Jolie, Opinion, My Medical Choice, N.Y. TIMES (May 14, 2013), 
https://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html [https://perma.cc/
H8DP-LS3P]. 
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immediate chemical environment in the body) on the ways genes are 
expressed are only beginning to be understood; and (3) for the rare 
cases of clear genetic-disease causation, treatment can only be 
symptomatic, since we have no “cures” at the genetic level.5 
 In fact, the holy grail of genomic medicine has always been the 
ability not just to identify dangerous gene mutations but to fix them: 
to go into a patient’s cells and change a dangerous DNA sequence to 
a healthy one. There have been efforts to do “gene therapy” by using 
viruses and other vectors to add desired DNA into the patient’s cells. 
There have been some limited successes6 but also some catastrophic 
failures, most infamously the death of a teenage boy in Pennsylvania7 
and cases of leukemia-like side effects in France.8 In hindsight, the 
problems were probably due to insufficient knowledge about the 
DNA-delivery mechanisms.9 
Now a new “gene-editing” technology, called CRISPR (or 
CRISPR-Cas9), may have the potential to provide a safe and effective 
way to cut out mutated sequences of DNA and paste in normal 
variants. As is so often the case in science, it is actually a new 
application of old knowledge—in this case, about the immune systems 
of bacteria. There is a long way to go before CRISPR becomes part of 
patient care, but, for the first time, there seems to be a way to 
leapfrog the use of potentially risky vectors to deliver DNA into a 
patient’s cells. The promise and potential value of the technology is 
reflected in the epic struggle underway over the foundational patent 
rights, featuring MIT and the Broad Institute on one side and the 
University of California-Berkeley and several European luminaries 
 
 5. Irwin Fridovich et al., Human Genetic Disease: Management of Genetic Disease, 
ENCYCLOPEÆDIA BRITANNICA, https://www.britannica.com/science/human-genetic-disease/
Management-of-genetic-disease [https://perma.cc/GQ4Z-VJPS]. 
 6. There is a rare eye disease (choroideremia), for example, where in a trial of “14 
patients [who] receiv[ed] a single injection into the back of the eye of a virus containing 
the missing gene” that caused their visual impairment, “there was a significant gain in 
vision across the group of patients as a whole .	.	. which was sustained for up to five years 
at the last follow up.” Gene Therapy Breakthrough in Treating Rare Form of Blindness, 
NIHR OXFORD BIOMEDICAL RES. CTR. (Oct. 8, 2018), https://oxfordbrc.nihr.ac.uk/gene-
therapy-breakthrough-in-treating-rare-form-of-blindness/ [https://perma.cc/VM7M-GH6V]. 
 7. Sheryl Gay Stolberg, The Biotech Death of Jesse Gelsinger, N.Y. TIMES MAG., 
Nov. 28, 1999, at 136, 137–38.  
 8. Andrew Pollack, F.D.A. Halts 27 Gene Therapy Trials After Illness, N.Y. TIMES 
(Jan. 15, 2003), https://www.nytimes.com/2003/01/15/us/fda-halts-27-gene-therapy-trials-
after-illness.html [https://perma.cc/D96D-9J6D]. 
 9. Id. 
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on the other—a biomedical Clash of Titans.10 Meanwhile, in 2015 a 
Chinese research team reported the first successful gene-editing 
intervention in nonviable human embryos,11 followed last year by a 
Chinese scientist’s claim to have edited the genome of twin baby 
girls.12 
The rapid development of CRISPR technology—in particular, 
the ethically dubious Chinese activities—has spurred consternation, 
debate, and governance proposals among scientists, bioethicists, 
lawmakers, and regulators. The contributors to this Symposium are 
all significant contributors to this emerging discourse. In this 
Symposium, our contributors explain gene-editing technology and 
explore its significant implications for law, ethics, regulation, and 
health policy from their varied perspectives. In this Introduction, I 
will give a brief, “CRISPR for Lawyers” overview of the technology 
and then provide a synopsis of each of the contributions to this 
Symposium. 
I.  HOW CRISPR WORKS 
CRISPR (pronounced “crisper,” like the lettuce drawer in the 
refrigerator) stands for Clustered Regularly Interspaced Short 
Palindromic Repeats.13 These are short, repeating sequences in the 
DNA of E. coli and other bacteria that were discovered by Japanese 
researchers in the 1980s.14 DNA is made up of long, two-stranded 
chains of four chemical building blocks, or bases: A,T,C, and G.15 The 
specific arrangement, or sequence, of these bases determines the 
 
 10. John Conley, Clash of Titans: The Fight Over the CRISPR Gene-Editing Patent 
Rights, ROBINSON BRADSHAW: PRIVACY REP. (Oct. 8, 2018), 
https://theprivacyreport.com/2018/10/08/clash-of-titans-the-fight-over-the-crispr-gene-editing-
patent-rights/ [https://perma.cc/HNF4-TQMD]. 
 11. David Cyranoski & Sara Reardon, Chinese Scientists Genetically Modify Human 
Embryos, NATURE (Apr. 22, 2015), https://www.nature.com/news/chinese-scientists-
genetically-modify-human-embryos-1.17378 [https://perma.cc/N3PN-JVB4]. 
 12. Dennis Normile, CRISPR Bombshell: Chinese Researcher Claims to Have Created 
Gene-Edited Twins, SCIENCE (Nov. 26, 2018, 1:10 PM), https://www.sciencemag.org/
news/2018/11/crispr-bombshell-chinese-researcher-claims-have-created-gene-edited-twins 
[https://perma.cc/HB4X-F52G]. 
 13. Brad Plumer et al., A Simple Guide to CRISPR, One of the Biggest Science Stories 
of the Decade, VOX (Dec. 27, 2018), https://www.vox.com/2018/7/23/17594864/crispr-cas9-
gene-editing [https://perma.cc/N6AM-MBMA]. 
 14. Id. 
 15. Richard J. Roberts et al., Nucleic Acid, ENCYCLOPÆDIA BRITANNICA, 
https://www.britannica.com/science/nucleic-acid#ref594016 [https://perma.cc/8KXY-WVD3]. 
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nature of the organism—in simplest terms, whether it’s a bacterium or 
me.16 
The CRISPR regions of bacteria were an enigma to the scientists 
who first noticed them. Their function was unknown for about twenty 
years, when food scientists using bacteria to make yogurt figured out 
that they are part of the bacteria’s immune system.17 These scientists 
realized that the CRISPR sequences resemble the DNA of viruses.18 
In fact, the CRISPR sequences are taken from viral DNA that the 
bacteria has captured during past viral invasions.19 When a new viral 
attack occurs, the bacteria’s immune system compares the virus’s 
genetic material to the sequences stored in CRISPR; if it detects a 
match, it launches enzymes to cut up the incoming viral DNA and 
repel the invasion.20 
The details of this recognize-and-destroy process have proved 
critical to developing CRISPR’s gene-editing potential. But first a bit 
more terminology: An organism’s genome is the entirety of its DNA; 
genes are those DNA sequences that function to build, or encode, 
proteins.21 Genes account for only a small portion of the DNA in the 
genome.22 Other portions of the genome have regulatory functions, 
controlling when particular genes switch on and off, while other areas 
have no known current function.23 RNA is a single-stranded cousin of 
DNA that performs many functions in the cell.24 
The bacterial CRISPR sequences are always accompanied by 
genes that code for enzymes (a class of proteins that facilitate 
chemical reactions) that can cut DNA.25 The original CRISPR 
scientists called them Cas (for CRISPR-associated) genes.26 Later 
research revealed that when viruses invade a bacterial cell, the 
 
 16. Id. 
 17. Plumer et al., supra note 13. 
 18. Id. 
 19. Id. 
 20. Id. 
 21. Help Me Understand Genetics, GENETICS HOME REFERENCE (May 14, 2019), 
https://ghr.nlm.nih.gov/primer [https://perma.cc/72WD-LN52]. 
 22. Jonathan Henninger, The 99 Percent .	.	. of the Human Genome, HARV. U.: SCI. 
NEWS (Oct. 1, 2012), http://sitn.hms.harvard.edu/flash/2012/issue127a/ [https://perma.cc/
ECM6-4HV9]. 
 23. Id. 
 24. Carl Zimmer, Breakthrough DNA Editor Born of Bacteria, QUANTA MAG. (Feb. 
6, 2015), https://www.quantamagazine.org/crispr-natural-history-in-bacteria-20150206/ 
[https://perma.cc/3Q9J-D2CE]. 
 25. Plumer et al., supra note 13. 
 26. Id. 
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CRISPR regions produce RNA versions of the viral DNA sequences 
that it has captured and stored.27 These RNA sequences are cradled 
by the Cas enzymes and carried around the cell.28 When an RNA 
sequence encounters its viral DNA counterpart, it latches on and the 
Cas enzyme cuts the DNA, which stops the virus from replicating.29 
Current CRISPR gene-editing technology mimics this natural 
process. Researchers at the University of California-Berkeley chose a 
Cas enzyme called Cas9.30 They supplied the enzymes with the RNA 
counterpart of the genetic sequence they wanted to edit—the target 
gene.31 The RNA finds and binds to the target DNA and the Cas9 
enzymes cut it at its two ends.32 With the target gene excised, the cell 
can be induced to make a new one.33 In the simplest application, the 
CRISPR mechanism finds and cuts out a “defective” gene—for 
example, one that causes a single-gene disease such as cystic fibrosis, 
hemophilia, or sickle cell disease—and the cell replaces it with a 
normal one.34 CRISPR technology can also be used to introduce a 
new gene into the space.35 
This image provides a simple visual representation of how 
CRISPR-Cas9 is used to find and cut a target gene (the g in gRNA 
stands for guide; PAM is a DNA sequence adjacent to the target 
sequence that Cas9 recognizes36): 
 
 
 27. Id. 
 28. Id. 
 29. Id. 
 30. Id. 
 31. Id. 
 32. Id. 
 33. Id. 
 34. Id. 
 35. Zimmer, supra note 24. 
 36. ADDGENE, CRISPR 101: A DESKTOP RESOURCE 9, 24–25 (2d ed. 2017), 
https://bit.ly/2uRYyG0 [https://perma.cc/ACU8-SLX3].  
97 N.C. L. REV. 1041 (2019) 




Image Credit: Marius Walter, GRNA-Cas9, WIKIMEDIA 
COMMONS (Sept. 25, 2017), https://commons.wikimedia.org/
wiki/File:GRNA-Cas9.png [https://perma.cc/9RSM-DDL8]. 
This image is licensed under the Creative Commons 
Attribution-ShareAlike 4.0 International license. See 
Attribution-ShareAlike 4.0 International License, CREATIVE 
COMMONS, https://creativecommons.org/licenses/by-sa/4.0/
legalcode [https://perma.cc/65BG-NRTQ]. 
CRISPR is not the first gene-editing technology. Other 
approaches include Zinc-finger nucleases (“ZFN”) and transcription 
activator-like effector nucleases (“TALENs”).37 ZFN, which dates to 
the early 1990s, employs custom-engineered proteins that find, bind 
to, and cut target DNA sequences.38 ZFN improved on prior 
technology by significantly improving the accuracy of gene editing, in 
particular by reducing “off-target” edits that hit the wrong DNA 
sequences with unpredictable consequences.39 However, ZFN’s 
 
 37. Id. at 53. 
 38. Thomas Gaj, Charles A. Gersbach & Carlos F. Barbas III, ZFN, TALEN, and 
CRISPR/Cas-Based Methods for Genome Editing, 31 TRENDS BIOTECHNOLOGY 397, 
398–99 (2013). 
 39. Id. at 400–01. 
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custom engineering of proteins for each new target gene makes it 
slow, expensive, and inefficient.40 TALENs, which appeared in 2009, 
is generally similar to ZFN but simpler and more efficient.41 CRISPR 
represents a major advance over both in terms of efficiency and 
accuracy.42 
There is a long way to go before CRISPR gene editing becomes 
part of everyday patient care, but it has the potential both to “fix” the 
causes of single-gene diseases and to contribute to the prevention or 
treatment of diseases that are caused by a complex interaction of 
genes and environmental factors, including cancer and heart disease.43 
Such uses seem—at least at first glance—to be ethically 
unproblematic, though there are worries about such safety issues as 
off-target edits.44 But other possible uses are already engendering 
profound ethical concerns. Those uses include enhancement, or gene 
editing to improve on normal human traits;45 editing human sperm or 
egg cells, which raises concerns about the intergenerational protection 
of those who might inherit edited genomes;46 gene editing of embryos, 
the subject of the recent Chinese claims;47 gene editing of animals, for 
a variety of purposes;48 and attempting to alter ecology, as in the 
proposed use of CRISPR to eliminate malarial mosquitoes.49 Such 
concerns are the subject of many of the Articles in this Symposium. 
 
 40. ADDGENE, supra note 36, at 8.  
 41. J. Boch et al., Breaking the Code of DNA Binding Specificity of TAL-Type III 
Effectors, 326 SCIENCE 1509, 1509–12 (2009); Gaj et al., supra note 38, at 399. 
 42. ADDGENE, supra note 36, at 9. 
 43. See id. at 15; Mark Shwartz, Target, Delete, Repair, STAN. MED. (2018), 
https://stanmed.stanford.edu/2018winter/CRISPR-for-gene-editing-is-revolutionary-but-it-
comes-with-risks.html [https://perma.cc/QVZ5-ZLZZ]. 
 44. Gaj et al., supra note 38, at 402. 
 45. See, e.g., Shwartz, supra note 43. 
 46. See, e.g., Jianhua Luo, Here’s What We Known About CRISPR Safety – And 




 47. See, e.g., Normile, supra note 12. 
 48. See, e.g., Preetika Rana & Lucy Craymer, Big Tongues and Extra Vertebrae: The 
Unintended Consequences of Animal Gene Editing, WALL ST. J. (Dec. 14, 2018), 
https://www.wsj.com/articles/deformities-alarm-scientists-racing-to-rewrite-animal-dna-
11544808779 [https://perma.cc/BYJ3-U87M]; see also THE NETH. COMM’N ON GENETIC 
MODIFICATION (COGEM), CRISPR & ANIMALS: IMPLICATIONS OF GENOME EDITING 
FOR POLICY AND SOCIETY 5–6 (2018).  
 49. See, e.g., Megan Molteni, Here’s the Plan to End Malaria with CRISPR-Edited 
Mosquitos, WIRED (Sept. 24, 2018, 11:00 AM), https://www.wired.com/story/heres-the-
plan-to-end-malaria-with-crispr-edited-mosquitoes/ [https://perma.cc/XTE4-FU9Q]; see 
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II.  SUMMARY OF THE ARTICLES 
The Articles in this issue are ordered generally according to 
theme. The first three deal in various ways with the ethics and legality 
of human gene editing. In Human Gene-Editing Research, Nancy 
King’s primary concern is the creation of inheritable gene changes. 
Her worries include the perpetuation of dangerous outcomes and the 
use of gene editing for enhancement rather than treatment. 
Expressing skepticism about global enforcement mechanisms, she 
argues rather for transparency, ongoing discussion, and the 
development of best practices. 
Next, Vence Bonham and Lisa Smilan’s Somatic Genome Editing 
in Sickle Cell Disease uses the history of sickle cell disease to explore 
the issue of equitable access to gene-editing treatments. Sickle cell 
disease is a prime candidate for the early application of somatic gene 
editing, but, as the authors document, the history of the treatment of 
people living with the disease is one of discrimination and health 
inequities. They offer ethical prescriptions for policymakers in an 
effort to avoid a repeat of that tragic story. 
Then, in Editing Humanity, Paul Enríquez examines the legality 
of human germline editing from multiple legal perspectives. He 
concludes that the Food and Drug Administration has ample current 
authority to regulate the practice but offers an innovative 
constitutional argument against efforts to ban germline gene-editing 
technologies. He proposes organizing possible uses of germline 
editing along an ethical continuum and using this continuum as a 
blueprint for future regulation. 
A second group of Articles addresses gene editing in relation to 
animals and the environment. Rebecca Walker and Matthias Eggel 
focus on the ethics of using animals to model potential human 
applications of CRISPR. In Replacement or Reduction of Gene-Edited 
Animals in Biomedical Research, they identify the inherent ethical 
tension in the trend toward reducing the number of animals used 
while at the same time replacing mice and rats with more 
“complex”—and thus more humanlike—species such as primates. 
In Before We Make a Pig’s Ear of It, Karen Meagher and Paul 
Thompson use recent nuisance suits against the North Carolina hog-
 
also Dylan Matthews, The Bold Plan to End Malaria with a Gene Drive, VOX (Sept. 26, 
2018, 5:03 PM), https://www.vox.com/science-and-health/2018/5/31/17344406/crispr-
mosquito-malaria-gene-drive-editing-target-africa-regulation-gmo [https://perma.cc/HG2Q-
RZ39]. 
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farming industry as a vehicle for thinking about the ethics of the gene 
editing of livestock. They argue for new bioethical frameworks that 
combine divergent perspectives as policymakers grapple with ethical 
problems at the intersection of the environment, public health, and 
the legitimate needs of agriculture. 
Governing Extinction in the Era of Gene Editing, by Jonas 
Monast, explores CRISPR technology as a conservation tool, 
including such uses as improving the genetic diversity of endangered 
species, controlling invasive species, and even reviving extinct species. 
The problem is that, whereas traditional conservation methods allow 
time and space for debating competing values, CRISPR-based 
conservation may move too fast. Monast offers a framework based in 
the Endangered Species Act to ensure that conservation uses of gene 
editing undergo appropriate public policy analysis. 
Three more Articles examine some of the health implications of 
gene editing. Legal and Ethical Implications of CRISPR Applications 
in Psychiatry, by Alexandra Foulkes and colleagues, addresses 
psychiatry’s increasing focus on the genomic correlates of many 
conditions. The authors identify some of the conditions that are 
especially promising for gene-editing treatment, as well as the special 
clinical challenges that CRISPR presents in the mental-health 
context. They conclude with some thoughts about the ethical and 
legal issues that are likely to arise, focusing particularly on the 
vulnerability of psychiatric patients who are likely to enlist in gene-
editing research. 
In DIY CRISPR, Christi Guerrini, Evan Spencer, and Patricia 
Zettler explore the overlooked and unregulated world of “citizen 
scientists” doing CRISPR research on their own, and sometimes on 
themselves. The authors’ extensive interview study reveals a 
surprisingly robust—and generally effective—self-regulatory regime. 
But their interviews also identify emerging challenges that may 
portend an increase in risky experimentation.  
Then, in Gene Therapy’s Field of Dreams, Laura Hercher and 
Anya Prince consider the critical question of who will pay for gene 
therapy. It is expensive and, because it is individualized, it is likely to 
remain so. Consequently, cost should be a fundamental concern, lest 
we slip into a world of “genetic haves and have-nots,” a world in 
which health inequalities are even more profound than they are now. 
In our final Article, The Pick-and-Shovel Play, Jacob Sherkow 
and Christopher Scott take a bioethical perspective on the role of 
patents in the development of gene-editing technology. While the 
97 N.C. L. REV. 1041 (2019) 
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debate thus far has been largely limited to the propriety of patents on 
gene-editing technologies themselves, the authors urge greater 
attention to the vectors that are used for introducing gene-editing 
mechanisms into the body. They contend that some commercial 
players have shrouded their vector information in secrecy, raising 
serious ethical and safety issues about the therapies in which those 
vectors are used. 
 
